Idorsia Pharmaceuticals has claimed FDA approval for aprocitentan as a treatment for resistant hypertension, becoming the first drug in the endothelin receptor antagonist class for that indication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback